Letter
Reply

https://doi.org/10.1067/mjd.2001.109858Get rights and content

Section snippets

To the editor:

We thank Dr Prince and colleagues for their critical comments and the report of failure to liposomal encapsulated doxorubicin in two cases of cutaneous T-cell lymphoma (CTCL). Every new treatment needs a good portion of criticism, and it is the same with the old compound doxorubicin delivered by a new technology, the pegylated liposomes. Prince et al raise 4 main questions:

  • 1.

    Do all patients with CTCL respond to the new doxorubicin formulation? The answer is no. In our pilot study1 including 6

References (2)

Cited by (0)

View full text